Nanoporous silica coupled MALDI-TOF MS detection of Bence-Jones proteins in human urine for diagnosis of multiple myeloma

Long, Shuping; Qin, Qin; Wang, Yuning; Yang, Yi; Wang, Yan; Deng, Anmei; Qiao, Liang; Liu, Baohong

doi:10.1016/j.talanta.2019.03.067

Cited by 21 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A well-establish method of assessment of MM or other plasma cell dyscrasias is the detection of paraproteins in serum or urine by protein electrophoresis or immunofixation [ 99 ]. Efforts have been made in recent years to develop novel methods of paraprotein detection in urine due to the limitations associated with conventional methods, including low sensitivity and highly laborious protocols [ 155 ]. Nanomaterials have become increasingly popular with a wide range of applications in the biomedical field.…”

Section: Urinementioning

confidence: 99%

“…Nanomaterials have become increasingly popular with a wide range of applications in the biomedical field. Long et al recently developed a highly sensitive and specific novel method of paraprotein detection in MM using macroporous ordered silica foams (MOSF) for Bence Jones protein enrichment coupled with matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) [ 155 ]. The association of paraproteinemia with other haematological malignancies such as primary cutaneous marginal zone lymphoma [ 156 ] indicates the potential clinical use of urinary paraprotein detection.…”

Section: Urinementioning

confidence: 99%

See 1 more Smart Citation

Clinical Proteomics of Biofluids in Haematological Malignancies

Dunphy

O’Mahoney

Dowling

et al. 2021

IJMS

View full text Add to dashboard Cite

Since the emergence of high-throughput proteomic techniques and advances in clinical technologies, there has been a steady rise in the number of cancer-associated diagnostic, prognostic, and predictive biomarkers being identified and translated into clinical use. The characterisation of biofluids has become a core objective for many proteomic researchers in order to detect disease-associated protein biomarkers in a minimally invasive manner. The proteomes of biofluids, including serum, saliva, cerebrospinal fluid, and urine, are highly dynamic with protein abundance fluctuating depending on the physiological and/or pathophysiological context. Improvements in mass-spectrometric technologies have facilitated the in-depth characterisation of biofluid proteomes which are now considered hosts of a wide array of clinically relevant biomarkers. Promising efforts are being made in the field of biomarker diagnostics for haematologic malignancies. Several serum and urine-based biomarkers such as free light chains, β-microglobulin, and lactate dehydrogenase are quantified as part of the clinical assessment of haematological malignancies. However, novel, minimally invasive proteomic markers are required to aid diagnosis and prognosis and to monitor therapeutic response and minimal residual disease. This review focuses on biofluids as a promising source of proteomic biomarkers in haematologic malignancies and a key component of future diagnostic, prognostic, and disease-monitoring applications.

show abstract

Section: Urinementioning

confidence: 99%

Section: Urinementioning

confidence: 99%

Clinical Proteomics of Biofluids in Haematological Malignancies

Dunphy

O’Mahoney

Dowling

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…A more convenient method than the intact protein MS method is the high-throughput version that is MALDI-Tof MS, the characteristics [9,[44][45][46] of which include (1) having a shorter data collection time (< 1 min/sample); (2) having a lower cost; (3) both urine-based and blood-based samples are eligible, and having confirmed that blood-based samples may be most useful for peripheral blood MM recurrence; and (4) having low-quality resolution, lacks chromatographic separation before MS analysis, and having a low sensitivity.…”

Section: Mass Spectrometrymentioning

confidence: 99%

Progress in the application of minimal residual disease detection in multiple myeloma

Zuo

2021

J Hematopathol

View full text Add to dashboard Cite

Currently, multiple myeloma is an incurable malignant plasma cell neoplasm, and the incidence rate ranks second in terms of hematological malignancies. Most of the patients are diagnosed at an age between 65 and 74 years, with a median age of 69 years. After the introduction of novel drugs or therapeutic methods, the treatment efficacy became significantly improved in multiple myeloma patients. Minimal residual disease is considered to be the most important reason for relapse in multiple myeloma patients after complete remission, which is significantly related to progression-free survival and overall survival. Therefore, minimal residual disease testing is essential for multiple myeloma patients after treatment. Several high-sensitivity technologies are used to detect minimal residual disease both inside and outside of the bone marrow of multiple myeloma patients after treatment, including cytology technology, molecular biology, and imaging technologies. In recent years, most of these minimal residual disease monitoring assays have made great progress. In this review, we focus on the characteristics and progress of the technologies that have been applied in multiple myeloma patients.

show abstract

“…Massive progress in proteomic technologies, including mass spectrometry (MS), opens new opportunities for the detection of cancer-associated biomarkers obtained via non-invasive liquid biopsy. Long et al has recently used nanoporous silica coupled MALDI-TOF-MS to detect Bence-Jones protein from the urine of patients with multiple myeloma with high specificity and sensitivity [ 80 ]. Moreover, MALDI-TOF-MS based total serum protein fingerprinting has also shown high sensitivity and specificity for the diagnosis of liver cancer [ 81 ].…”

Section: Liquid Biopsy Analysis: Advanced Technologies Manifest Nementioning

confidence: 99%

Liquid Biopsy is Instrumental for 3PM Dimensional Solutions in Cancer Management

Líšková

Samec

Koklesová

et al. 2020

JCM

View full text Add to dashboard Cite

One in every four deaths is due to cancer in Europe. In view of its increasing incidence, cancer became the leading cause of death and disease burden in Denmark, France, the Netherlands, and the UK. Without essential improvements in cancer prevention, an additional 775,000 cases of annual incidence have been prognosed until 2040. Between 1995 and 2018, the direct costs of cancer doubled from EUR 52 billion to EUR 103 billion in Europe, and per capita health spending on cancer increased by 86% from EUR 105 to EUR 195 in general, whereby Austria, Germany, Switzerland, Benelux, and France spend the most on cancer care compared to other European countries. In view of the consequent severe socio-economic burden on society, the paradigm change from a reactive to a predictive, preventive, and personalized medical approach in the overall cancer management is essential. Concepts of predictive, preventive, and personalized medicine (3PM) demonstrate a great potential to revise the above presented trends and to implement cost-effective healthcare that benefits the patient and society as a whole. At any stage, application of early and predictive diagnostics, targeted prevention, and personalization of medical services are basic pillars making 3PM particularly attractive for the patients as well as ethical and cost-effective healthcare. Optimal 3PM approach requires novel instruments such as well-designed liquid biopsy application. This review article highlights current achievements and details liquid biopsy approaches specifically in cancer management. 3PM-relevant expert recommendations are provided.

show abstract

Nanoporous silica coupled MALDI-TOF MS detection of Bence-Jones proteins in human urine for diagnosis of multiple myeloma

Cited by 21 publications

References 30 publications

Clinical Proteomics of Biofluids in Haematological Malignancies

Clinical Proteomics of Biofluids in Haematological Malignancies

Progress in the application of minimal residual disease detection in multiple myeloma

Liquid Biopsy is Instrumental for 3PM Dimensional Solutions in Cancer Management

Contact Info

Product

Resources

About